Clinical Trial Update: Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating weekly cilengitide in combination with paclitaxel in adults with advanced, unresectable solid tumors, including breast cancer subtypes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Taxol (paclitaxel)
• cilengitide (cilengitide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Solid Neoplasm, Estrogen Receptor Negative | Phase 1 | Status: COMPLETED